Squibb’s revenge?
Executive Summary
The rumored acquisition of Bristol-Myers Squibb by GlaxoSmithKline would be the latest and largest ripple effect from the Bristol/Squibb integration in 1989. The two CEOs who drove the Glaxo/SmithKline merger at the end of the 1990s (Glaxo's Richard Sykes and SmithKline's Jan Leschly) were both former Squibb execs who learned firsthand the perils of a lack of scale during a period of consolidation. While both Sykes and Leschly have retired, the logic and momentum behind the strategy they pursued is a prime factor driving GSK's interest in Bristol...
You may also be interested in...
Roche/Genentech Keeps Commitment To External Cancer Innovation
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
US FDA Eases Changes For Certain Sterile Injectable Container Closure Materials
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.
Unprecedented To Lawful: Regulatory Precedent Needed For Cannabinoids’ Use In Supplements?
“This is truly uncharted territory because we’ve never had this situation,” says CHPA regulatory VP David Spangle. Asking Congress instead to instruct FDA to first determine a safe daily limit would be a threatening precedent for the supplement market, says CRN CEO Steve Mister. “That really turns DSHEA on its head.”
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: